摘要
The output of Taiwan’s pharmaceutical industry in the second quarter of 2011 reached NT$ 14.93 billion. Facing the imminent seventh drug-price adjustment under Taiwan’s National Health Insurance (NHI) policy, the domestic manufacturers became more conservative. Although healthcare insurance claims grew 6% in the first half of 2011, most companies opted for inventory adjustments, which lead to significant declines in pharmaceutical outputs....